Matt Holman joined Philip Morris International as vice president of U.S. scientific engagement and regulatory strategy in August 2022. In this role, he leads the development and execution of PMI’s U.S. tobacco harm reduction strategy. He works to build understanding and support for smoke-free products and the science related to tobacco harm reduction among stakeholders. He also supports and advises PMI’s U.S. regulatory strategy, identifying approaches needed to address current and future regulations. Prior to joining PMI, Holman spent two decades as a regulatory scientist at the U.S. Food and Drug Administration, where he served in numerous leadership positions. He joined the FDA’s Center for Tobacco Products one year after it was created as a division director in the Office of Science. He ended his tenure at the FDA as the director of the Office of Science. In his positions within the Office of Science, he helped create the marketing application review programs and signed final actions for millions of tobacco products.
